LKB1 is a tumor susceptibility gene for the Peutz-Jeghers cancer syndrome and is a target for mutational inactivation in sporadic human malignancies. LKB1 encodes a serine/threonine kinase that has critical roles in cell growth, polarity and metabolism. A novel and important function of LKB1 is its ability to regulate the phosphorylation of CREB-regulated transcription co-activators (CRTCs) whose aberrant activation is linked with oncogenic activities. However, the roles and mechanisms of LKB1 and CRTC in the pathogenesis of esophageal cancer have not been previously investigated. In this study, we observed altered LKB1-CRTC signaling in a subset of human esophageal cancer cell lines and patient samples. LKB1 negatively regulates esophageal cancer cell migration and invasion in vitro. Mechanistically, we determined that CRTC signaling becomes activated because of LKB1 loss, which results in the transcriptional activation of specific downstream targets including LYPD3, a critical mediator for LKB1 loss-of-function. Our data indicate that de-regulated LKB1-CRTC signaling might represent a crucial mechanism for esophageal cancer progression.
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Introduction
Esophageal cancer is one of the most common malignancies and leading causes of cancer deaths worldwide (Lam, 2000; Enzinger and Mayer, 2003; Kuwano et al., 2005; Rustgi, 2006; Klein and Stoecklein, 2009; Vallbohmer et al., 2010) . Esophageal squamous cell carcinoma (ESCC) accounts for the majority of esophageal cancers but in recent years the incidence of esophageal adenocarcinoma has increased dramatically, particularly in Western countries. Esophageal cancers are highly invasive and metastatic, which account for the high rate of cancer death. At the time of diagnosis, the majority of patients have cancers that have already invaded the underlying muscle layers and at least 50% have metastasized to nearby and distant sites such as lymph nodes, livers and lungs. Genetically, esophageal cancer is associated with the aberrant expression of cellular factors such as epidermal growth factor receptor (EGFR), p53, cyclin D1 and p16. However, the exact molecular mechanisms that contribute to the initiation and progression of esophageal cancer remain unclear. Therefore, it will be of great significance to elucidate the molecular mechanisms underlying these processes and this knowledge will help us understand esophageal cancer initiation and progression and develop effective diagnostics and treatments for this disease.
Studies have implicated the LKB1 (STK11) kinase in cancer development. LKB1 was first recognized as a tumor-suppressor gene because its mutations cause Peutz-Jeghers syndrome, characterized by gastrointestinal hamartoma with an increased cancer risk (Giardiello et al., 2000; van Lier et al., 2010) . This gene was later found to be a target for mutational inactivation in human malignancies including non-small cell lung carcinoma (Sanchez-Cespedes et al., 2002; Carretero et al., 2004; Ji et al., 2007; Matsumoto et al., 2007; Makowski and Hayes, 2008; Komiya et al., 2010; Mahoney et al., 2009) , cervical carcinoma (Wingo et al., 2009) , melanoma (Guldberg et al., 1999; Rowan et al., 1999) and others (Sanchez-Cespedes, 2007) . The LKB1 gene encodes a serine/threonine kinase essential for the activation of AMPK (AMP-activated protein kinase) and 12 AMPK-related kinases; thus, it regulates multiple signaling pathways in cell growth, cell polarity and metabolism (Hezel and Bardeesy, 2008; Shackelford and Shaw, 2009; Luo et al., 2010) . Currently, information regarding the exact roles and mechanisms underlying LKB1-mediating tumor suppression remains limited. A novel function of LKB1 is its ability to negatively regulate the CREB-regulated transcriptional co-activator (CRTC) family members, CRTC1-3 (Conkright et al., 2003; Iourgenko et al., 2003) . CRTC proteins are normally phosphorylated and sequestered in the cytoplasm (Jin et al., 2004) . They become dephosphorylated under high levels of cAMP, leading to nuclear translocation. Nuclear CRTCs interact with the CREB transcription factor, thereby enhancing CREB target gene expression. CRTCs are critical for anabolic glucose/fatty acid metabolism, thus regulating energy balance (Altarejos et al., 2008; Breuillaud et al., 2009) . CRTC1 was originally identified to be a fusion partner with the Notch transcriptional co-activator, MAML2, because of a t(11;19) chromosomal translocation in mucoepidermoid carcinoma (Tonon et al., 2003) . CRTC1 function thus becomes aberrantly activated, which contributes to CRTC1-MAML2 oncogenic activities (Coxon et al., 2005; Wu et al., 2005) . CRTC1 co-activator function is attenuated by salt-induced kinases (SIKs), because SIKs phosphorylate CRTC1, preventing CRTC1 from entering the nucleus and activating CREB transcription (Katoh et al., 2006) . As SIKs enzymatic activities are dependent on LKB1, it is anticipated that LKB1 deregulation impacts CRTC1 functional activities. This is supported by a recent study that indicated somatic loss of LKB1 in lung cancer is associated with CRTC1 activation (Komiya et al., 2010) . However, questions still remain regarding the exact functional consequences of CRTC activation in tumorigenesis and whether CRTC activation is a key mediator in LKB1 loss.
Since no previous studies have investigated LKB1 in esophageal cancer, we decided to examine possible LKB1 genetic aberrations and the role that LKB1-CRTC has in the pathogenesis of this disease. We discovered LKB1 downregulation in a subset of human esophageal cancer cell lines and patient samples, and LKB1 negatively regulated esophageal cancer cell migration and invasion. Importantly, LKB1 downregulation resulted in deregulated LKB1-CRTC signaling, a novel mechanism that possibly mediates critical cellular aspects of esophageal cancer progression. Our study indicates that LKB1-CRTC deregulation might have a critical role in esophageal cancer progression.
Results

Intact LKB1 expression is lost or reduced in esophageal cancer cells
To evaluate the potential role(s) of LKB1 in the pathogenesis of esophageal cancer, we first determined the expression status of LKB1 in a series of human ESCC lines. Through western blot analysis, we observed that one of our tested 13 ESCC cell lines, TE-4, appeared to have a complete ablation of LKB1 protein expression, and the vast majority of the other ESCC cell lines exhibited reduced LKB1 expression levels as compared with immortalized normal esophageal epithelial cells, Het1A ( Figure 1a and Supplementary Figure 1) . These data indicate aberrant LKB1 expression in a subset of esophageal cancer cells.
Somatic mutations of the LKB1 gene were found in several types of human cancers including non-small cell lung cancer and cervical cancer (Sanchez-Cespedes et al., 2002; Carretero et al., 2004; Matsumoto et al., 2007; Wingo et al., 2009) . Epigenetic silencing of the LKB1 gene promoter was also reported in tumors associated with Peutz-Jeghers syndrome (Esteller et al., 2000) . To investigate the mechanisms underlying LKB1 downregulation in esophageal cancer cells, we first determined whether LKB1 loss could be due to epigenetic silencing. Cells were treated with a DNA methyltransferase inhibitor (5-Aza-2 0 -deoxycytidine) and/or a histone deacetylase inhibitor (Trichostatin A). However, we did not observe increased LKB1 protein expression, suggesting that epigenetic inactivation may not cause LKB1 downregulation (Supplementary Figure 2) . We then performed mutation studies to detect any possible somatic LKB1 gene mutations. All the exons of the LKB1 gene obtained by PCR-amplifying genomic DNA isolated from esophageal cancer cell lines were sequenced. We found that TE-4 cells carry two nucleotide changes in the LKB1 gene (Supplementary Figure 3) : a deletion mutation (c.842delC) in exon 6 (resulting in a truncated product 1-284aa (p.Pro281ArgfsX4)); and a mis-sense mutation (c.1062C>G) in exon 8 (F to I at position 354 (p.L354F)), which could be a nucleotide polymorphism as it was previously found present in the Asian population (Launonen et al., 2000) . As the chromatogram did not show the presence of the wild-type allele of the LKB1 gene, it thus suggested loss of heterozygosity. The COSMIC database indicates that another ESCC line KYSE-270 carries a mutation in LKB1 (c.1_1302del1302), resulting in frame deletion of LKB1 proteins (p.M1_*434del). These data thus reveal that a subset of esophageal cancer cells contains somatic mutations in the LKB1 gene, likely resulting in reduced or absent intact LKB1 protein expression.
To determine whether human esophageal tumors exhibit abnormal LKB1 expression, we obtained eight pairs of freshly frozen esophageal tumor samples and their corresponding matching normal mucosa tissues. The tumor samples consisted of seven cases of esophageal adenocarcinoma and one case of squamous cell carcinoma (Supplementary Table 1 ). Western blot analysis revealed that six of these human esophageal tumors had significantly reduced LKB1 expression in comparison with their respective normal mucosa tissues (Figure 1b) . Interestingly, all these six tumors showing reduced LKB1 expression are esophageal adenocarcinoma. Tumor biopsies are often contaminated with normal tissues such as stromal cells, but our data strongly indicate a possibility that LKB1 is downregulated in a subset of esophageal tumors.
LKB1 loss promotes esophageal cancer cell migration and invasion
Studies with a mouse model of non-small cell lung cancer showed that LKB1 inactivation enhanced K-RAS-mediated metastasis and affected tumor initiation and differentiation, revealing a role for LKB1 in cancer metastasis (Ji et al., 2007; Carretero et al., 2010) . However, the role of LKB1 in esophageal cancer pathogenesis remains unclear. As we observed abnormal LKB1 expression in human esophageal cancer cell lines and esophageal tumors, we decided to investigate whether LKB1 regulates esophageal cancer cell migration and invasion properties.
First, we determined the functional effects of LKB1 expression in LKB1-deficient esophageal cancer cells. We infected LKB1-deficient TE-4 cells with retroviruses that expressed wild-type LKB1 or control viruses generated from the empty vectors, and obtained stably transduced cells. Transduced LKB1 expression was confirmed by western blot analysis ( Figure 2a ). Morphologically, parental and control viruses-infected LKB1-deficient TE-4 cells exhibited a dispersed, fibroblast-like phenotype, but showed a cohesive, epithelial cell-like morphology after LKB1 expression ( Figure 2b and not shown). However, this morphological change does not appear to represent a typical mesenchymalto-epithelial transition change, as we observed downregulation of the epithelial marker E-cadherin and upregulation of the mesenchymal marker N-cadherin following LKB1 expression (Supplementary Figure 4) . These data are consistent with the previous microarray data showing that LKB1 expression reduced E-cadherin transcript levels in LKB1-deficient lung cancer cells (Ji et al., 2007) . To evaluate whether LKB1 regulates cell migration and invasion, we performed wound-healing and transwell assays, and found that LKB1 expression in LKB1-deficient cells significantly prolonged wound closure at both 24 (not shown) and 48 h after wound introduction ( Figure 2c ) and reduced esophageal cancer cell migration across a basement membrane toward the serum attraction (Figure 2d ). Moreover, LKB1 re-introduction showed a moderate increase in cell proliferation rate ( Figure 2e ). These data indicate that LKB1 expression in LKB1-deficient esophageal cancer cells promoted a change in cell morphology and decreased wound closure and cell invasion. 
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We also determined the functional consequences of LKB1 knockdown in LKB1-expressing esophageal cancer cells. We infected LKB1-expressing KYSE70 cells with lentiviruses expressing short hairpin RNAs targeting LKB1 or luciferase gene (Luc) as a control and achieved 490% of LKB1 protein knockdown ( Figure 3a ). LKB1-expressing KYSE70 cells showed an epithelial cell-like morphology, but after LKB1 knockdown, they adopted a fibroblast-like morphology ( Figure 3b ). Wound-healing assays also indicated that, after both 24 (not shown) and 48 h, LKB1-knockdown cells filled in the scratch wound more extensively than control cells did ( Figure 3c ). Transwell assays showed that LKB1 knockdown significantly enhanced the number of the cells migrated across a basement membrane toward the serum attraction ( Figure 3d ). However, LKB1-knockdown cells showed a very moderate decrease in cell proliferation (Figure 3e ). These data show that LKB1 knockdown induced a change in cell morphology, facilitated wound closure and enhanced invasion.
Previous studies have shown that LKB1 expression caused cell growth suppression in a p53-dependent manner (Tiainen et al., 1999 (Tiainen et al., , 2002 ). We did not observe an LKB1 growth suppression effect, which could be due to the fact that the two cell lines we used contain non-functional p53, which we confirmed by the absence of p21 induction after mitomycin C treatment (Supplementary Figure 5) . Thus, our data indicate that the LKB1 regulation of cell proliferation is cell-context dependent, while the ability of LKB1 to regulate cell migration/invasion appears not to depend on functional p53. Therefore, our data strongly suggest that LKB1 downregulation promotes esophageal cancer invasion and progression.
LKB1 regulates CRTC1 phosphorylation and sub-cellular localization LKB1 regulates multiple pathways; however, it is unclear which specific LKB1-dependent signaling pathway(s) contributes to LKB1 loss-mediated promotion of cell migration and invasion. As LKB1-dependent SIKs negatively regulate CRTCs (Jin et al., 2004) and as CRTC1 activation is linked with oncogenic transformation (Tonon et al., 2003; Wu et al., 2005; Komiya et al., 2006) , we, therefore, hypothesized that LKB1 downregulation would result in SIKs inactivation and lead to an enrichment of hypophosphorylated CRTC1. Hypophosphorylated CRTC is then predicted to enter the nucleus and co-activate CREB-mediated target gene transcription, which potentially contributes to esophageal cancer cell migration and invasion.
To test this hypothesis, we first determined whether LKB1 regulates endogenous CRTC1 phosphorylation. We found that LKB1-deficient TE-4 cells display a major CRTC1 faster mobility form (indicative of a hypophosphorylated species), while LKB1-expressing cells showed various CRTC mobility forms (indicative of phosphorylated CRTC1) (Supplementary Figure 6) , supporting the observation that LKB1 loss is correlated with hypophosphorylated CRTC1. Importantly, LKB1 expression in LKB1-deficient cells results in increased levels of the phosphorylated form of CRTC1, while the vector control cells have a hypophosphorylated form similar to that of the parental cells (Figure 4a and supplementary Figure 7) . Conversely, the lentiviralmediated LKB1 knockdown in the LKB1-expressing cells leads to increased levels of the hypophosphorylated form of CRTC1 (Figure 4d ). These data indicate that LKB1 regulates CRTC1 phosphorylation in esophageal cancer cells.
Nuclear translocation of CRTC1 is an important step in signal-mediated transcriptional activation. We found that LKB1-deficient cells displayed significant nuclear CRTC1 localization (Figure 4b , upper panels), correlated with its hypophosphorylation. However, LKB1 expression results in predominantly cytoplasmic localization of CRTC1, which is correlated with a shift in CRTC1 phosphorylation (Figure 4b , lower panels) and 
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Y Gu et al also consistent with our sub-cellular fractionation experiment showing that the levels of nuclear CRTC1 were reduced and the levels of cytoplasmic CRTC1 increased following LKB1 expression (Figure 4c ). Conversely, LKB1 knockdown in LKB1-expressing cells led to increased levels of nuclear CRTC1 and reduced levels of cytoplasmic CRTC1 assayed by both cell staining and sub-cellular fractionation assays (Figures 4e and f) . Therefore, our data indicate that LKB1 regulates CRTC1 phosphorylation and sub-cellular localization. LKB1 downregulation leads to CRTC1 dephosphorylation and enhanced nuclear CRTC1, which is functionally active in promoting transcriptional regulation. Thus, there is deregulated LKB1-CRTC1 signaling in human esophageal cancer following LKB1 downregulation.
LKB1 loss leads to the upregulated expression of CRTC1 target genes and one of the targets LYPD3 mediates enhanced cell migration and invasion in vitro To evaluate downstream targets for deregulated LKB1-CRTC1 signaling, we first analyzed our microarray data (E-MEXP-340 in ArrayExpress) of Hela cells transiently transfected with CRTC1 or vector control and identified a list of genes that contains CRTC1-regulated genes. We specifically focus on LYPD3 (C4.4A), because it is the gene showing the highest upregulation (with a 5.7-fold change, Pp0.0004) (Supplementary Figure 8) . Importantly, LYPD3 is a glycosylphosphatidylinositol (GPI)-anchored metastasis-associated protein that has a low degree of homology to the receptor for the urokinasetype plasminogen activator (Rosel et al., 1998; Wurfel et al., 2001) . We analyzed whether LKB1 regulates LYPD3 expression. We found that LKB1 re-expression in LKB1-deficient TE-4 cells resulted in a significant decrease in LYPD3 expression (Figure 5a ). Conversely, LKB1 knockdown in LKB1-expressing KYSE-70 cells led to a significant LYPD3 upregulation (Figure 5b ). We also determined another target gene, NR4A2, in parallel, which is critical for the growth of lung cancer cells (Komiya et al., 2010) . We found that NR4A2 shows similar changes in response to LKB1 modulation, but its expression is generally lower compared with LYPD3 (Supplementary Figure 9) . These data indicate that LKB1 negatively regulates transcription of CRTC1 target genes including LYPD3.
As LYPD3 is associated with cancer metastasis and its expression is enhanced in LKB1-deficient and knockdown cells, we speculate that LYPD3 is an important mediator for LKB1 loss activities. Therefore, we knocked down LYPD3 expression in LKB1-deficient cells by about 70% (Figure 5c ). We observed that LYPD3 knockdown led to a significant reduction of cell migration/invasion potentials in wound-healing and transwell assays (Figures 5d and e) , but did not significantly affect cell proliferation (Figure 5f ). These data indicate that LYPD3 is an important target for the deregulated LKB1-CRTC1 pathway that contributes to enhanced migration and invasion in esophageal cancer cells.
LYPD3 expression is regulated by LKB1-CRTC-CREB signaling axis
We next investigated a potential critical downstream component of LKB1-CRTC1 signaling axis, the transcription factor CREB, because CRTC functions as a relatively dedicated transcriptional co-activator for CREB-mediated transcription. First, we blocked CREB activities via the expression of A-CREB, a wellcharacterized dominant-negative mutant that specifi- Deregulated LKB1-CRTC signaling in esophageal cancer Y Gu et al cally blocks CREB binding to DNA (Ahn et al., 1998) by infecting cells with retroviral murine stem cell virus (MSCV)-based A-CREB. We found that there is a significant, but relatively moderate reduction in the expression level of the CRTC1 target LYPD3, which could be due to low level of A-CREB expression that cannot fully counteract CREB activities (Figure 6a ). Second, we depleted CREB expression by 490% and found that CREB depletion led to a significant reduction in LYPD3 expression in LKB1-deficient esophageal cancer cells (Figure 6b ). These data indicate that LKB1 loss-induced LYPD3 upregulation is at least partially due to CREB activities.
To further determine whether the LYPD3 promoter is regulated by LKB1-CRTC1, we cloned the LYPD3 gene promoter sequence (À526 to þ 43) into the upstream of a luciferase reporter (pGL3 basic) and observed that the LYPD3 promoter reporter had reduced activities when LKB1 was expressed (Figure 6c) . Also, exogenous CRTC1 expression greatly enhanced LYPD3 promoter activities (Figure 6d ). Furthermore, CRTC1 and CREB were found enriched on the LYPD3 promoter in LKB1-deficient TE-4 cells by chromatin immunoprecipitation (ChIP) assay (Figures 6e and f) . These data indicate that LKB1 negatively regulates CRTC1 transcriptional co-activator function and CRTC1 co-activates CREB to promote transcription of target gene LYPD3.
LYPD3 is overexpressed in human ESCC tumors
To assess LYPD3 expression in ESCCs, we performed immunohistochemical staining on paraffin-embedded multi-tumor array with anti-LYPD3 antibodies. In the adjacent normal mucosa's squamous epithelium, there was strong LYPD3 staining in the cell membranes of differentiated cells, but no staining in the basal cell compartment (Figure 6g ), which is consistent with previous staining data (Hansen et al., 2008) . On the other hand, we found that LYPD3 is overexpressed in various stages of cancer development, including carcinoma in situ and carcinoma at more advanced stages. Interestingly, LYPD3 appears to have altered subcellular localization from the cell membrane to intracellular staining, though it was presently unclear about the functional significance of nuclear LYPD3 expression.
Discussion
In this study, we observed LKB1 downregulation in a subset of human esophageal cancer cell lines and 
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Y Gu et al patient samples. LKB1 negatively regulates esophageal cancer cell migration: the loss of LKB1 promotes cell migration whereas LKB1 expression has repressive effects. Mechanistically, LKB1-dependent CRTC signaling is activated following LKB1 loss, which results in the transcriptional activation of downstream targets. One of the target genes, LYPD3, appears to be a critical mediator for LKB1 loss-of-function in cell migration and invasion, because LYPD3 knockdown abrogated enhanced migration and invasion in LKB1-deficient cells. This is the first study that links the potential role of deregulated LKB1 in cancer metastasis to CRTC target gene regulation. The LKB1-dependent CRTC signaling pathway is likely to be an important target for developing diagnostic and treatment strategies for esophageal cancer. Although LKB1 mutational inactivation has been observed in several human malignancies, the role of LKB1 in esophageal cancer was not previously reported. We identified a reduction or loss of LKB1 expression in a significant subset of human esophageal cancer cell lines and patient tumor samples, suggesting that LKB1 downregulation has an important role in esophageal cancer pathogenesis. Owing to the small sample size of patient tumors used in this study and the presence of variable amounts of normal stromal tissue in biopsy samples, it is difficult to determine the exact incidence of aberrant LKB1 expression in esophageal cancer. In addition, the lack of a specific anti-LKB1 reagent for immunohistochemistry has hindered the analysis of primary tumor samples. However, this is the first study to investigate LKB1 protein expression in esophageal tumors and we observed LKB1 null phenotype in one tumor cell line and downregulation in six out of eight primary tumor samples. Future gene expression and mutational studies of the LKB1 gene in a larger set of patient samples, correlated with the information of cancers at various clinical stages, will elucidate the extent of aberrant LKB1 expression in esophageal cancer and critical events of cancer development that LKB1 might be involved in.
The exact role of LKB1 in the initiation and progression of esophageal cancer is unclear, although LKB1 was shown to regulate cell proliferation, survival and migration. Our studies provided strong evidence that LKB1 loss has a pro-metastatic effect on cell-based Figure 6 The LYPD3 promoter is directly regulated by LKB1-CRTC1-CREB signaling axis, and LYPD3 is overexpressed in esophageal squamous cancer. (a) A-CREB expression significantly reduced LYPD3 expression in LKB1-deficient TE-4 cells. TE-4 cells were infected with MSCV-based retroviruses that express FLAG-tagged A-CREB and green fluorescent protein (GFP) from a bicistronic mRNA under the control of MSCV promoter or vector control expressing only GFP. GFP-positive cells were sorted by fluorescence-activated cell sorting and protein lysates and RNA were then prepared. FLAG-tagged A-CREB expression was confirmed by western blotting with anti-FLAG antibodies. LYPD3 expression was evaluated by real-time reverse transcriptase (RT)-PCR. The infection experiments were performed twice independently (n ¼ 2, Po0.05). (b) CREB depletion significantly decreased LYPD3 expression in TE-4 cells. The level of CREB knockdown was evaluated by western blot analysis and the levels of LYPD3 were assayed by real-time RT-PCR (n ¼ 2, Po0.05). (c) LKB1 re-expression in the LKB1-deficient TE-4 cells repressed LYPD3 promoter activities (n ¼ 3, Po0.05). (d) CRTC1 expression promoted LYPD3 promoter activities (n ¼ 3, Po0.05). (e, f) CRTC1 and CREB were enriched on the LYPD3 promoter in TE-4 cells by ChIP assays (n ¼ 3, Po0.05). (g) LYPD3 was overexpressed in esophageal squamous carcinoma by immunohistochemical staining. Upper panels showed the hematoxylin and eosin-stained images of normal and tumor sections, and lower panels showed the immunohistochemistry-stained images using an LYPD3 antibody.
Deregulated LKB1-CRTC signaling in esophageal cancer Y Gu et al assays, because LKB1 expression negatively regulates cell migration and invasion, as demonstrated by our gain-of-function or loss-of-function data. These data suggest that LKB1 has a possible role in regulating cancer metastasis, indicating that LKB1 downregulation possibly contributes to the highly invasive properties of human esophageal cancers.
LKB1 regulates multiple kinases and, thus, has the potential to modulate different signaling activities. As activation of CRTC signaling because of a chromosomal translocation contributes to oncogenic transformation (Tonon et al., 2003; Coxon et al., 2005; Wu et al., 2005) , we determined CRTC expression and found that esophageal cancer cells express all three CRTC genes at various levels (Supplementary Figure 10) . Owing to functional similarity among three CRTCs, we focused on CRTC1 in this study that would reflect the overall CRTC functions. We found that LKB1 loss enhanced the levels of functional CRTC1 as indicated by the enhanced hypophosphorylated, nuclear form of CRTC1 and enhanced CRTC1 target expression while LKB1 expression had the opposite effects. These data indicate that CRTC activation might be an important therapeutic target for esophageal cancer. Various steps regulate CRTC activities including phosphorylation, nuclear import and active transcriptional complex assembly, but the mechanisms are incomplete (Altarejos and Montminy, 2011) . For instance, other kinases including microtubule affinity regulating kinase 2 and kinases upstream of AMPK such as CaMKK (Ca2 þ /calmodulin-dependent kinase kinase) might have roles in regulating CRTC phosphorylation. Therefore, understanding the molecular mechanisms will be important in developing strategies for manipulating CRTC activities.
LYPD3 appears to be critical in mediating LKB1 function in regulating esophageal cell migration and invasion. LYPD3 is upregulated in metastasizing tumor cells, but showed restricted expression in normal adult tissues (Rosel et al., 1998; Seiter et al., 2001; Wurfel et al., 2001; Hansen et al., 2008) . The exact biochemical functions of LYPD3 are unknown; however, it was shown to interact with the adhesion proteins laminin-1, laminin-5 and galectin-3, which might promote metastasis and matrix invasion (Paret et al., 2005) . With regard to esophageal cancer, LYPD3 was proposed as a histological marker of invasion and metastasis for ESCC (Hansen et al., 2008) . Our data extend the finding that LYPD3 is overexpressed in a high percentage of ESCCs, suggesting an important role in ESCC development. We also showed that LYPD3 is the CRTC1 transcriptional target and its expression is regulated by LKB1-CRTC-CREB signaling axis. Furthermore, LYPD3 knockdown in LKB1-deficient cells inhibits cell migration and invasion, providing direct evidence for a role of LYPD3 in cell migration, and suggesting the importance of LYPD3 in mediating LKB1 loss-offunction effects in esophageal cancer. These data also highlight the importance of LYPD3 expression and function regulation in interfering with cancer progression. Although our data points to a critical role for LYPD3 in mediated the LKB1-CRTC-CREB signaling, other target genes potentially contribute to esophageal cancer cell migration and invasion. For instance, one of genes upregulated by CRTC1 in our gene expression profiling analysis is STYK1/NOK. This gene encodes a serine/threonine/tyrosine kinase 1, and its overexpression in pre-B cells, Baf3 was found to cause growth factor-independent proliferation and colony formation in vitro and induced tumorigenesis and metastasis in nude mice (Liu et al., 2004; Chen et al., 2005) . Also, it is unclear whether there is a role of STYK1 in regulating SIKs or AMPKs that might affect CRTC phosphorylation and function. With an oncogenic role for STYK, it will be worthy to determine whether STYK is a target for LKB1-CRTC signaling in esophageal cancer and how it might regulate LKB1-CRTC signaling.
It remains undetermined whether activation of CRTC family members is a major signaling event in mediating the effect of LKB1 loss-of-function in esophageal cancer. It was previously shown that stress-induced AMPK activation causes CRTC phosphorylation and affects its function. It should be noted that the LKB1-associated effects on CRTC phosphorylation, transcription activation of target genes as well as cell migration and invasion properties were observed in the absence of AMPK activation. Therefore, it is possible that the cellular effects because of the altered LKB1-CRTC signaling will be further affected by cellular environments such as glucose levels and hypoxia conditions. The comparisons of downstream targets regulated by LKB1 and CRTC under various cellular conditions will provide us with the common targets that LKB1 and CRTC regulate as well as other distinct signaling regulated by both pathways.
In summary, we identified a subset of esophageal tumors that exhibit LKB1 expression downregulation. LKB1 negatively regulates esophageal cancer cell migration, suggesting a critical role for LKB1 in regulating cancer invasion and metastasis. CRTC1, an important co-activator regulated by LKB1, becomes activated because of aberrant LKB1 expression, and the LKB1-CRTC1 target, LYPD3 is one of the major effectors that regulate cell migration and invasion. Our data enable us to provide a working model of these signaling interactions and effects (Figure 7) . We propose that LKB1 downregulation activates pathways that lead to CRTC activation and gene transcription. The transcriptional activation of target genes including LYPD3 leads to enhanced cell migration and invasion, which likely contributes to metastatic potential. Our data warrant future studies to understand the importance of LKB1 and CRTC signaling in esophageal cancers and to investigate CRTC activation as a target for cancers with LKB1 downregulation.
Materials and methods
Plasmids
The following plasmids were obtained: pBABE-FLAG-LKB1 from AddGene (Cambridge, MA, USA); pGIPZ lentiviral LYPD3 short hairpin RNA, pLKO.1 lentiviral LKB1 short hairpin RNA and pLKO.1 lentiviral CREB short hairpin RNA constructs from Open Biosystems (Huntsville, AL, USA). pMSCV-A-CREB-IRES-GFP and pFLAG-CMV2-CRTC1 were previously described . The LYPD3 promoter sequence (À526 to þ 43) was sub-cloned into the pGL3 plasmid (Promega, Madison, WI, USA).
Antibodies
The antibodies were obtained from commercial sources: LKB1 rabbit (Cell Signaling Technology, Danvers, MA, USA; 3050); LKB1 mouse (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA; 32245); CRTC1 (Rockland Immunochemicals Inc., Gilbertsville, PA, USA; 600-401-936); CREB (Millipore, Billerica, MA, USA; 06-863); LYPD3 (MBL International, Woburn, MA, USA; LS-A9857); HDAC1 (Fisher Scientific, Pittsburgh, PA, USA; PA1-860); p21 (Santa Cruz, sc-397) and bactin (Sigma, St Louis, MO, USA, A5316).
Mutational studies
Genomic DNA was isolated from esophageal cancer cell lines. Various exons of the LKB1 gene were amplified by PCR and sequenced. The primer sequences are shown in Supplementary  Table 2 .
Cell culture and viral transduction Het1A, a human SV40-immortalized esophageal epithelial cell line was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Het1A cells were grown in BEGM medium (Biowhittaker Inc, Chesterbrook, PA, USA). The TE series (Nishihira et al., 1993) and KYSE series (Shimada et al., 1992) of esophageal cancer cells were grown in RPMI-1640 containing 10% fetal bovine serum. Retroviral and lentiviral production and transduction were previously described . Stably transduced cells were obtained and maintained by puromycin selection.
Western blot analysis and subcellular fractionation
Frozen tumor samples and their matching control tissues were obtained from the Pathology Tumor Bank at the University of Florida. Preparation of whole cell lysates and western blotting analysis were performed as described previously (Wu et al., 2000) . Nuclear protein fractions were isolated using a Nuclear Extract Kit (Active motif).
Cell staining and reporter assays Cell staining and luciferase-based reporter assays were performed as previously described (Wu et al., 2000) .
Wound-healing assay Wound-healing assay was performed as previously described (Rodriguez et al., 2005) . In brief, cells were plated on culture dishes to create a confluent monolayer. A wound was created by manually scraping the cell monolayer with a yellow tip and the cells were washed and cultured with medium containing RPMI-1640 with 2% calf serum. Cell images were then acquired at 0, 24 and 48 h after wound was created.
Transwell assay
The invasive ability of esophageal cancer cells was determined according to a previously described procedure (Sattler et al., 2002; Andl et al., 2003) . The membranes of transwell chambers (8 mm pore size polycarbonate membrane, Corning Costar Corp., Lowell, MA, USA) were coated with 20 mg/ml fibronectin (Invitrogen, Carlsbad, CA, USA) at 37 1C overnight. Inserts were placed in a 24-well plate containing full medium with serum. Cells (5 Â 10 4 ) in serum-free medium were plated in the upper chamber in triplicate. After 24 or 48 h, cells that migrated through and attached to the bottom of the membrane were fixed and stained with crystal violet. Migrated cells in three different fields were counted. Three replicated experiments were performed and error bars represented the standard error of the mean.
Real-time reverse transcriptase-PCR RNA was isolated with the Trizol Reagent (Invitrogen) and purified by the Qiagen Column with in column DNase digestion. Complementary DNA was generated using a GeneAmp RNA PCR kit (Applied Biosystems, Carlsbad, CA, USA) from 2 mg of total RNA. Real-time PCR was performed using the 7500 Fast Real-Time PCR System (Applied Biosystems) with the SYBR Green PCR Core Reagents Kit (Applied Biosystems). Glyceraldehyde 3-phosphate dehydrogenase was used as an internal control to normalize gene expression levels. Data represented were based on triplicate experiments. The primer sequences are listed in Supplementary Table 3 .
Chromatin immunoprecipitation
The ChIP assays were performed based on the Millipore ChIP protocol with minor modifications as previously described . Briefly, cells were fixed with 1% formaldehyde for 10 min and lyzed with the ChIP sonication buffer, followed by sonication to shear DNA to lengths between 200 and 800 bp. The DNA protein complex was then immunoprecipitated with the CRTC1 or CREB antibodies or control immunoglobulin G. The ChIP DNA was purified and eluted with 100 ml of H 2 O. ChIP DNA (2.5 ml) was used for the realtime PCR analysis using the primers flanking the CREBbinding site of LYPD3 target promoter. The primer sequences are listed in Supplementary Table 4 .
Immunohistochemical staining
Formalin-fixed paraffin-embedded ESCC microarray slides containing paired tumor and adjacent normal mucosa were described previously (Lee et al., 2010) . These slides were heated Figure 7 A model of LKB1-CRTC deregulation in esophageal cancer progression. LKB1 downregulation activates pathways that lead to CRTC activation and gene transcription. The transcriptional activation of target genes including LYPD3 leads to enhanced cell migration and invasion, which likely contributes to metastatic potential.
Deregulated LKB1-CRTC signaling in esophageal cancer Y Gu et al at 50 1C for 1 h before being deparaffinized and rehydrated. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 10 min. Optimal staining with rabbit anti-LYPD3 (LS-A9857, MBL) required 25 min of heat antigen retrieval in 10 mM citrate buffer pH 6.0. Sections were sequentially blocked with normal serum, avidin and biotin before the application of rabbit anti-LYPD3 (1:200) overnight at 4 1C. Slides were stained using the ABC-Elite kit (Vector Labs, Burlingame, CA, USA) and counter-stained with hematoxylin (SurgiPath, Richmond, IL, USA).
Statistical analyses of experimental data Independent Student's t-test was used to analyze data from proliferation-or migration-or invasion-or real-time PCR-experiments.
